| HOME >> BIOLOGY >> TECHNOLOGY |
GAAP results, respectively. The $39.9 million charge for the six months
ended June 30, 2008 included $14.5 million charged to cost of sales, $6.6
million charged to research and development, $6.2 million charged to
selling, general and administrative, $6.6 million charged to interest
expense and $6.0 million charged through equity earnings of unconsolidated
entities, net of tax. The $1.0 million charge for the six months ended
June 30, 2007 was charged to selling, general and administrative. These
charges have been excluded from net income or loss because they have a
significant impact on results yet do not occur on a consistent or regular
basis in the Company's business.
(d) Compensation costs of $12.7 million and $48.9 million associated with
stock-based compensation expense in the first six months of 2008 and 2007
GAAP results, respectively, including $0.6 million and $0.2 million
charged to cost of sales, $2.3 million and $0.7 million charged to
research and development and $9.8 million and $48.0 million charged to
selling, general and administrative. The $48.0 million charged to
selling, general and administrative during the six months ended June 30,
2007 includes $45.2 million of costs associated with stock option
acceleration and conversion in connection with our acquisition of Biosite,
Inc.
(e) A write-off in the amount of $2.0 million and $1.2 million during the
six months ended June 30, 2008 and 2007, respectively, relating to
inventory write-ups recorded in connection with the acquisitions of Panbio
Limited and BBI Holdings Plc. during the first quarter of 2008 and
Biosite, Inc during the second quarter of 2007.
(f) Charges totaling $15.6 million associated with the write-off of debt
origination costs and a prepayment premium paid upon early extinguis
'/>"/>
| SOURCE Inverness Medical Innovations, Inc. Copyright©2008 PR Newswire. All rights reserved |